BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2024, and highlighted select corporate achievements.
“Our robust second quarter continues to demonstrate the successful transformation of Innoviva. We have strong performance across multiple fronts, driven by our core GSK royalties portfolio and accelerating growth from our commercial products, GIAPREZA®, XACDURO® and XERAVA®,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “We remain committed to enhancing shareholder value through thoughtful capital allocation and operational excellence. We also are excited about our portfolio of strategic healthcare assets, where we continue to see potential for significant value creation.”
Mr. Raifeld added, “In addition to driving strong operational delivery from our critical care and infectious disease platform IST, we continue to expand its global footprint and enhance recognition. Our partner in China, Zai Lab, successfully obtained regulatory approval for XACDURO®, bringing us closer to making XACDURO® available to all patients globally. In the U.S, important treatment guidelines and guidance updates recognized our key products, underscoring their life-saving potential. XACDURO® was named the preferred agent for treatment of Carbapenem-resistant Acinetobacter baumannii infections in the 2024 Infectious Diseases Society of America (IDSA) treatment guidance. XERAVA® is recommended by the 2024 Surgical Infection Society (SIS) treatment guidelines for empiric therapy in the management of complicated intra-abdominal infection.”
Financial Highlights
- Royalty revenue: Second quarter 2024 gross royalty revenue from Glaxo Group Limited (“GSK”) was $67.2 million, compared to $65.7 million for the second quarter 2023.
- Net Product Sales: Second quarter 2024 net product sales were $21.7 million, which included $13.1 million from GIAPREZA®, $6.2 million from XERAVA®, and $2.4 million from XACDURO®, a 38% increase compared to $15.7 million for the second quarter 2023.
- License Revenue: Second quarter 2024 license revenue of $14.5 million included an $8 million milestone payment from our partner for the regulatory approval of XACDURO® in China and $6.5 million in non-recurring cost-sharing reimbursements from our partner for product development.
- Equity and long-term investments: Second quarter 2024 net unfavorable change in fair values of equity and long-term investments of $90.7 million was primarily attributable to lower share price of Armata Pharmaceuticals (“Armata”), despite continued operational progress.
- Net income: The change in fair values of our investments negatively impacted second quarter 2024 earnings, resulting in a net loss of $34.7 million, or ($0.55) basic per share, compared to a net income of $1.3 million, or $0.02 basic per share, for the second quarter of 2023.
- Share repurchases: During the second quarter 2024, Innoviva completed its $100 million share repurchase program by repurchasing 0.4 million shares, for a total amount of approximately $5.3 million.
- Cash and cash equivalents: Totaled $217.0 million. Royalty and net product sales receivables totaled $94.0 million as of June 30, 2024.
Key Business and R&D Highlights
-
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use: targeted antibacterial for the treatment of patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii calcoaceticus complex.
- In May 2024, XACDURO® was approved in China by the National Medical Products Administration (NMPA) for use in Chinese patients 18 years of age and older.
- In July 2024, XACDURO® was named as the preferred agent for the treatment of Carbapenem-resistant Acinetobacter baumannii infections, in combination with a carbapenem, in the updated 2024 IDSA treatment guidance.
- The World Health Organization considers Acinetobacter a top-priority pathogen worldwide that needs novel antibiotics1.
-
XERAVA® (eravacycline), for injection is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms in patients 18 years or older.
- In July 2024, XERAVA® was named as a recommended agent for empiric therapy in the updated 2024 SIS treatment guidelines for the management of complicated intra-abdominal infections. SIS also recommended XERAVA® be reserved for high-risk patients.
-
Zoliflodacin: a potential first-in-class, single dose, oral antibiotic in development for the treatment of patients with uncomplicated gonorrhea is currently being developed in partnership with The Global Antibiotic Research & Development Partnership (GARDP).
- Zoliflodacin has successfully completed Phase 3 clinical trials and the results were reported at ESCMID Global 2024. The Company expects to submit an NDA to the U.S. FDA in early 2025.
About Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.
Forward Looking Statements
This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA® and XACDURO® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (“COVID-19”); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
References
(1) Tala, B., Jad, A., Claude, A., Jihad, I., Chantal, L., Rakan, N.,& Eid, A. (2017). Risk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia. Front. Cell. Infect. Microbiol., 04 May 2017, Sec. Molecular Bacterial Pathogenesis Volume 7 – 2017: https://doi.org/10.3389/fcimb.2017.00156
| INNOVIVA, INC. | ||||||||||||||||
| Condensed Consolidated Statements of Income and Comprehensive Income | ||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
| Revenue: | ||||||||||||||||
| Royalty revenue, net (1) | $ |
63,742 |
|
$ |
62,265 |
|
$ |
122,157 |
|
$ |
119,123 |
|
||||
| Net product sales |
|
21,651 |
|
|
15,727 |
|
|
40,735 |
|
|
27,241 |
|
||||
| License revenue |
|
14,505 |
|
|
3,000 |
|
|
14,505 |
|
|
11,000 |
|
||||
| Total revenue |
|
99,898 |
|
|
80,992 |
|
|
177,397 |
|
|
157,364 |
|
||||
| Expenses: | ||||||||||||||||
| Cost of products sold (inclusive of amortization of inventory fair value adjustments) |
|
8,472 |
|
|
8,979 |
|
|
19,443 |
|
|
17,728 |
|
||||
| Cost of license revenue |
|
- |
|
|
- |
|
|
- |
|
|
1,600 |
|
||||
| Selling, general and administrative |
|
27,740 |
|
|
23,542 |
|
|
58,145 |
|
|
43,277 |
|
||||
| Research and development |
|
2,560 |
|
|
14,989 |
|
|
6,438 |
|
|
27,577 |
|
||||
| Amortization of acquired intangible assets |
|
6,440 |
|
|
4,958 |
|
|
12,880 |
|
|
8,763 |
|
||||
| Changes in fair values of equity method investments, net |
|
60,108 |
|
|
19,911 |
|
|
24,766 |
|
|
4,094 |
|
||||
| Changes in fair values of equity and long-term investments, net |
|
30,556 |
|
|
83 |
|
|
43,891 |
|
|
2,247 |
|
||||
| Interest and dividend income |
|
(3,474 |
) |
|
(3,553 |
) |
|
(7,873 |
) |
|
(6,918 |
) |
||||
| Interest expense |
|
5,802 |
|
|
4,382 |
|
|
11,653 |
|
|
8,809 |
|
||||
| Other expense, net |
|
973 |
|
|
1,896 |
|
|
2,209 |
|
|
3,242 |
|
||||
| Total expenses, net |
|
139,177 |
|
|
75,187 |
|
|
171,552 |
|
|
110,419 |
|
||||
| Income (loss) before income taxes |
|
(39,279 |
) |
|
5,805 |
|
|
5,845 |
|
|
46,945 |
|
||||
| Income tax expense (benefit), net |
|
(4,594 |
) |
|
4,525 |
|
|
3,998 |
|
|
10,800 |
|
||||
| Net income (loss) and comprehensive income (loss) | $ |
(34,685 |
) |
$ |
1,280 |
|
$ |
1,847 |
|
$ |
36,145 |
|
||||
| Net income (loss) per share | ||||||||||||||||
| Basic | $ |
(0.55 |
) |
$ |
0.02 |
|
$ |
0.03 |
|
$ |
0.54 |
|
||||
| Diluted | $ |
(0.55 |
) |
$ |
0.02 |
|
$ |
0.03 |
|
$ |
0.46 |
|
||||
| Shares used to compute net income (loss) per share | ||||||||||||||||
| Basic |
|
62,526 |
|
|
65,341 |
|
|
62,856 |
|
|
66,557 |
|
||||
| Diluted |
|
62,526 |
|
|
65,489 |
|
|
63,064 |
|
|
88,175 |
|
||||
| (1) Total net revenue is comprised of the following (in thousands): | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
| (unaudited) | (unaudited) | |||||||||||||||
| Royalties | $ |
67,198 |
|
$ |
65,721 |
|
$ |
129,069 |
|
$ |
126,035 |
|
||||
| Amortization of capitalized fees |
|
(3,456 |
) |
|
(3,456 |
) |
|
(6,912 |
) |
|
(6,912 |
) |
||||
| Royalty revenue, net | $ |
63,742 |
|
$ |
62,265 |
|
$ |
122,157 |
|
$ |
119,123 |
|
||||
| INNOVIVA, INC. | |||||
| Condensed Consolidated Balance Sheets | |||||
| (in thousands) | |||||
| (unaudited) | |||||
| June 30, | December 31, | ||||
2024 |
2023 |
||||
| Assets | |||||
| Cash and cash equivalents | $ |
217,003 |
$ |
193,513 |
|
| Royalty and product sale receivables |
|
93,980 |
|
84,075 |
|
| Inventory |
|
36,664 |
|
40,737 |
|
| Prepaid expense and other current assets |
|
10,630 |
|
25,894 |
|
| Property and equipment, net |
|
427 |
|
483 |
|
| Equity and long-term investments |
|
536,435 |
|
560,978 |
|
| Capitalized fees paid, net |
|
76,872 |
|
83,784 |
|
| Right-of-use assets |
|
3,118 |
|
2,536 |
|
| Goodwill |
|
17,905 |
|
17,905 |
|
| Intangible assets |
|
217,455 |
|
230,335 |
|
| Deferred tax asset, net |
|
11,446 |
|
- |
|
| Other assets |
|
2,982 |
|
3,267 |
|
| Total assets | $ |
1,224,917 |
$ |
1,243,507 |
|
| Liabilities and stockholders’ equity | |||||
| Other current liabilities | $ |
23,929 |
$ |
33,435 |
|
| Accrued interest payable |
|
3,422 |
|
3,422 |
|
| Deferred revenue |
|
855 |
|
1,277 |
|
| Convertible senior notes, due 2025, net |
|
191,659 |
|
191,295 |
|
| Convertible senior notes, due 2028, net |
|
255,623 |
|
254,939 |
|
| Other long-term liabilities |
|
72,065 |
|
71,870 |
|
| Deferred tax liabilities, net |
|
- |
|
563 |
|
| Income tax payable, long-term |
|
11,849 |
|
11,751 |
|
| Innoviva stockholders’ equity |
|
665,515 |
|
674,955 |
|
| Total liabilities and stockholders’ equity | $ |
1,224,917 |
$ |
1,243,507 |
|
| INNOVIVA, INC. | |||||||
| Cash Flows Summary | |||||||
| (in thousands) | |||||||
| (unaudited) | |||||||
| Six Months Ended | |||||||
| June 30, | |||||||
|
|
2024 |
|
|
|
2023 |
|
| Net cash provided by operating activities | $ |
80,765 |
|
$ |
63,866 |
|
|
| Net cash used in investing activities |
|
(43,038 |
) |
|
(35,722 |
) |
|
| Net cash used in financing activities |
|
(14,237 |
) |
|
(146,168 |
) |
|
| Net change | $ |
23,490 |
|
$ |
(118,024 |
) |
|
| Cash and cash equivalents at beginning of period |
|
193,513 |
|
|
291,049 |
|
|
| Cash and cash equivalents at end of period | $ |
217,003 |
|
$ |
173,025 |
|
|
